A Race Against Death: How Zhejiang University Hospital's Cardiovascular Center Saved a Critical Heart Failure Patient with Tongling Lifescience's Televad P50

2025-01-04

Heart failure, the end-stage progression of cardiovascular diseases, is notorious for its high morbidity and mortality rates—often deemed the "final battlefield" in cardiology. While traditional drug therapies offer symptomatic relief, and heart transplants face donor shortages, a groundbreaking solution has emerged in recent years: the percutaneous ventricular assist device (pVAD), a safer and more effective treatment that brings new hope to patients.

The pVAD is a minimally invasive device that delivers short-term circulatory support by implanting a catheter pump into the heart to directly pump blood from the left ventricle into the aorta. It is particularly vital for treating complex coronary artery disease, acute myocardial infarction with cardiogenic shock, and acute decompensated chronic heart failure.

Tongling Bionics Technology Ltd. (hereafter "Tongling Bionics"), a pioneer in pVAD R&D in China, has successfully developed the TeleVad P50. This device achieves breakthroughs in hemodynamics optimization, blood trauma reduction, fluid sealing, and core components (including micro-motors and low-hemolysis impellers). With advantages like minimal hemolysis, high flow capacity, and prolonged durability, it is currently undergoing multicenter clinical trials nationwide, earning high praise from physicians.

Recently, the cardiac surgery team led by Dr. Kong Minjian, Deputy Chief Physician at Zhejiang University Hospital's Cardiovascular Center (Bo'ao Branch), successfully deployed the TeleVad P50 to save a critically ill patient. After an arduous surgery, Dr. Kong retrograde-implanted the device via the aorta to restore the patient's cardiac pumping function. Following 7 days of support, the patient's ejection fraction (EF) rebounded from 10% post-op to 40%, culminating in a full recovery and discharge.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

WeChat official account

Anhui Tongling Bionics Technology Ltd.

Tel: 400 636 3262
E-mail: BD@telelife.com.cn

Add.: Building A7, National Health Big Data Industrial Park, Hefei High-tech Zone, Anhui, China

WeChat

Business license

-

NEWS

A Race Against Death: How Zhejiang University Hospital's Cardiovascular Center Saved a Critical Heart Failure Patient with Tongling Lifescience's Televad P50

COOKIES

COOKIES

Sorry，当前栏目暂无内容!

Sorry，The current column has no content!